Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200002/S012

EPi-Sense Guided Coagulation System

AtriCure, Inc. · Decision date Oct 7, 2025

FDA DECISIONP200002/S012

What did the FDA approve?

FDA records P200002/S012 as a supplement to PMA P200002, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 7, 2025.

FDA approval order statement

approval of a revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P200002.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Oct 7, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P200002/S012
Regulatory pathway
PMA supplement
Product code
OCM
Decision code
APPR
Decision date
Oct 7, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Surgical cardiac ablation device, for treatment of atrial fibrillation.

Product code
OCM
FDA device class
3

For the original device and its historical approval scope, see PMA P200002. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200002 · Original PMA

    EPi-Sense Guided Coagulation System

  2. P200002/S012 received

    Application receipt date recorded by FDA.

  3. P200002/S012 · FDA decision

    Normal 180 Day Track No User Fee

  4. P200002/S013 · Related supplement

    EPi-Sense ST Coagulation System

  5. P200002/S014 · Related supplement

    EPi-Sense and EPi-Sense ST Guided Coagulation System

  6. P200002/S015 · Related supplement

    EPi- Sense ST Coagulation System

Timeline entries are records held by MedtechLedger for P200002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200002

Product / regulatory recordCompanyPathwayDecision dateSource
AtriCure, Inc.PMA approvalApr 28, 2021FDA
AtriCure, Inc.PMA supplementNov 14, 2025FDA
AtriCure, Inc.PMA supplementMay 6, 2026FDA
AtriCure, Inc.PMA supplementSep 24, 2026FDA

Explore the linked device profile

Other records with product code OCM

Product / regulatory recordCompanyPathwayDecision dateSource
AtriCure, Inc.PMA supplementSep 24, 2026FDA
AtriCure, Inc.PMA supplementMay 6, 2026FDA
AtriCure, Inc.PMA approvalDec 14, 2011FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

AtriCure, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7555 Innovation Way, Mason, OH, 45040

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records